Skip to content

Two and a half years extra ART if treatment starts at 500 CD4s, not 350

EACS: Studies underline the need for better hepatitis C treatment

US state laws obstruct CDC recommendations for routine HIV testing

XDR-TB found in HIV-positive patients in India; rapid progression to death

UK report highlights homelessness link to IDUs acquiring hepatitis C, but not HIV

Defining, and then watching for, treatment failure

EACS: Switching to atazanavir maintains viral suppression, even in patients with protease resistance

EACS: Nevirapine studies highlight new first-line uses

EACS: Old campaigners: Belgians document long-term AIDS survival